Search results
Showing 1981 to 1995 of 2084 results for technology appraisal
Discontinued Reference number: GID-TA11181
Hypercholesterolaemia (primary), dyslipidaemia (mixed) - anacetrapib [ID1165]
Discontinued Reference number: GID-TA11175
In development Reference number: GID-TA11014 Expected publication date: TBC
Dexmedetomidine for treating agitation associated with schizophrenia [TSID10726]
In development Reference number: GID-TA11015 Expected publication date: TBC
In development Reference number: GID-TA11679 Expected publication date: TBC
Neuro-Cells stem-cell treatment for traumatic spinal cord injury [ID6588]
In development Reference number: GID-TA11629 Expected publication date: TBC
Secukinumab for treating moderate to severe hidradenitis suppurativa (TA935)
Evidence-based recommendations on secukinumab (Cosentyx) for active moderate to severe hidradenitis suppurativa (acne inversa) in adults.
In development Reference number: GID-TA11104 Expected publication date: TBC
In development Reference number: GID-TA11310 Expected publication date: TBC
Discontinued Reference number: GID-TA10234
Belatacept for the prevention of organ rejection in kidney transplantation [ID87]
Discontinued Reference number: GID-TAG239
psoriatic arthritis, which have led to positive recommendations in NICE technology appraisals, no such good-quality...
Stroke and transient ischaemic attack in over 16s: diagnosis and initial management (NG128)
This guideline covers interventions in the acute stage of a stroke or transient ischaemic attack (TIA). It offers the best clinical advice on the diagnosis and acute management of stroke and TIA in the 48 hours after onset of symptoms.
Eteplirsen for treating Duchenne muscular dystrophy [ID1003]
Discontinued Reference number: GID-HST10007
Apalutamide for treating non-metastatic, hormone-relapsed prostate cancer [ID1174]
Discontinued Reference number: GID-TA10377